BridgeMD
New treatment option for Pruritis
Official title Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
ClinicalTrials.gov ID: NCT06226610
What this study is testing
What is Dupilumab?
Dupilumab is an investigational medicine, given as an once-daily injectable medicine, being studied as a potential treatment for pruritis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Persons 18-60 year old with post-burn hypertrophic scars of any size which required grafting or epidermal autografting for an acute burn injury, with...
You likely can't join if
- Currently taking Dupixent for any other diagnosis
- known allergy to Dupixent
- pregnant and or lactating mothers
- anyone treated for pruritus using laser therapy
- currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications
- Currently taking steroids
See the full eligibility criteria
- Persons 18-60 year old with post-burn hypertrophic scars of any size which required grafting or epidermal autografting for an acute burn injury, with continued complaint of pruritus due to inadequate relief from...
- Currently taking Dupixent for any other diagnosis
- known allergy to Dupixent
- pregnant and or lactating mothers
- anyone treated for pruritus using laser therapy
- currently receiving adequate relief for pruritis under standard of care medical management by antihistamine or neuroleptic medications
- Currently taking steroids
- persons with developmental delays or otherwise unable to complete measures
- prisoners or anyone otherwise unable to give their own consent or who is not their own guardian
- one or more of the following existing disorders: conjunctivitis; any co-existing dermatological condition except burns; any type of cancer; requiring dialysis; chronic Stage 3 or higher kidney disease; biliary disorder...
- Persons unable to provide their own consent, including prisoners when their incarcerated status is not itself the focus of study, are routinely excluded from clinical trials at this site
- We further exclude persons with other dermatological conditions (other than burn) , which may have pruritis or pain associated with them and who may be treated with medications other than Dupixent, and whose perceived...
- We similarly exclude anyone treated for pruritis by laser therapy as their perceived benefit could confound our results.
The study team makes the final eligibility decision.
Where it's taking place
- Akron, Ohio, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Akron, Ohio, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.